focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-A "healthier rally" ahead?

Tue, 27th Mar 2018 11:57

* European stocks rise 1.4 pct * Wall Street, Asia surged on China-U.S. trade talks March 27 - Welcome to the home for real-time coverage of European equity markets brought toyou by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger toshare your thoughts on market moves: helen.reid.thomsonreuters.com@reuters.net A "HEALTHIER RALLY" AHEAD? (1052 GMT) We've had a "healthy" correction, but could the recent sell-off lead to a "healthy" rally? Barclays' equity derivative strategists see the possibility of a trade war keeping themarket on edge, which they say would allow some of the "excessive exuberance" to abate. Theypoint to a cooling in equity market valuations since the recent sell-off (see Barclays' chartsbelow) and sentiment among retail investors moderating. "In one sense, we view this as a healthy development, given it would provide an outlet forsome of the excess exuberance," say Barclays' strategists in a note. One thing to watch is how fast volatility normalises. Barclays notes that if this isgradual, it would be a sign that market sentiment was cautious and herald a return to "the“normal” grinding rally". "If equities do not recover sharply, we believe valuations have a better chance ofnormalising, which would set the stage for a healthier subsequent rally," Barclays concludes. (Kit Rees) ***** KEEPING TABS ON THE S&P'S 200-DAY MOVING AVERAGE (1005 GMT) Investors are increasingly looking at the S&P 500's 200-day moving average,especially after the two big sell-offs that roiled markets this year saw the bears surrender tothe bulls just when the U.S. benchmark index hit that level. The S&P fell more than 6 percent last week to end a tick above the 200-day average, but onMonday it staged a powerful bounce, indicating how crucial that level has become for the market. Going forward, any breach below it may well be seen as a negative signal and JCI Capitalfund manager Alessandro Balsotti believes that from now on investors will be monitoring it evenmore "religiously". And what about Europe? Well it's a different story: the STOXX 600 has been tradingbelow the 200-day average since early February. (Danilo Masoni) ***** SHARES SHRUG OFF WEAK EUROPEAN DATA BUT "PEAK GROWTH" NARRATIVE BUILDS (0950 GMT) Economic sentiment in the euro zone slipped for a third month in a row in March as managersin manufacturing, services and retail became slightly less optimistic, European Commission datajust showed. But stocks are taking this in their stride and have even accelerated their risefrom 1.2 percent to 1.5 percent since the data was published. A whole bunch of research this morning ahead of the publication noted, like DNB's dailynote, that "Eurozone macro data surprises have been more negative than positive recently" andthat "growth is strong, but no longer accelerating". For CMC Markets, "the beginning of possible micro fissures in the European growth story"and "momentum indicators ... flashing warning signs" may be an explanation as to why Europeanmarkets are having a hard time keeping up with their U.S. counterparts. In a strategy note on European equities this morning, HSBC said that its "economics team'sview of GDP growth momentum fading through the course of this year" backed investing in longerduration fixed income and in stocks with higher dividend yield for their "defensive attributes". On the trading floor however the consensus seems to be that the euro zone's economic healthstill backs an optimistic view of its shares. There can be "a lot of noise in macro data in thenear-term", Chris Dyer, director of global equity at Eaton Vance just told us. "Generally we think the European economy is on a good footing", Dyer, who is overweightEuropean equities, said, adding that the weakness in economic data will only become a concern ifit continues. Here's a chart by DNB showing the loss of growth momentum in Europe: (Helen Reid and Julien Ponthus) ***** OPENING SNAPSHOT: EUROPEAN STOCKS BOUNCE (0727 GMT) European shares are joining in a global relief rally in risk assets as trade tensions ease.Sectors which were hit hardest over the past few sessions, such as autos, basicresources and tech, are the biggest gainers early on. The biggest individual mover so far is France's Casino, which has jumped around 6percent after its Monoprix chain agreed to sell products via Amazon. This shows just how crucialit is for companies to demonstrate that they are keeping up with the times and exploring onlineopportunities. Regarding the spreadbetters and ESMA's restrictions on CFDs, it's a mixed bag following adecidedly negative start, with IG down slightly but both CMC and Plus500 making gains. Here's your opening snapshot: (Kit Rees) ***** WHAT'S ON THE RADAR FOR THE OPEN (0649 GMT) European stocks are set to surge with futures climbing 1.4 to 2.2 percent across the majorbenchmarks, riding the wave of rising equities worldwide after Wall Street indices had theirstrongest day in years as investors bet on a trade war détente. Retail stocks will be ones to watch after French supermarket group Casino struck a deal withAmazon to make groceries from its Monoprix chain of stores available on Amazon’s Prime Nowservice to Parisian customers this year. The partnership extends Amazon’s reach into the European grocery market, and while Casinoshares are seen rising 3 to 5 percent, the news could shake investors’ confidence in retailnames that are more behind the curve. In M&A news, GlaxoSmithKline shares are expected to rise 3 to 4 percent after the pharmacompany announced it was buying out Novartis’ stake in their consumer healthcare joint venturefor $13 billion. Novartis is seen up 1 percent. Another corporate break-up story from Akzo Nobel which is to sell its Specialty Chemicalsbusiness for $12.6 billion to U.S. private equity firm Carlyle Group and Singapore’s GIC –ending the simplification effort which began as the paint maker sought to evade a takeover fromPPG in April 2017. Its shares are set to rise 2 to 4 percent. Spreadbetters such as IG Group, CMC Markets and Plus500 are seen down 2 percent premarketafter a move from European markets regulator ESMA to crack down on contract-for-difference (CFD)trades offered to retail clients. (Helen Reid) ***** MORNING HEADLINE ROUND-UP (0637 GMT) Here's a round-up of key headlines for European companies this morning - note the news thatCasino's Monoprix is going to be teaming up with Amazon to sell groceries on Prime Nowin Paris. Casino's shares are seen up as much as 5 percent premarket. GSK buys Novartis stake in consumer healthcare venture for $13 bln H&M Q1 pretax dives in line with expectations, flags more markdowns Deutsche Bank seeks to replace CEO with Goldman executive -report Amazon wins grocery foothold in France through Monoprix deal Galliford Try to raise 158 mln stg to cover Carillion project costs Nordex sees lower sales, margins as wind industry tightens Akzo Nobel to sell unit to Carlyle, GIC for 10.1 bln euros (Kit Rees) ***** EUROPEAN STOCK FUTURES SURGE (0610 GMT) Futures for the major European stock markets have opened sharply higher, rising 1.1 to 1.8percent with the DAX in the lead, as investors place bets on a strong bounce at the open. Meanwhile analysts are still mulling what caused the late-afternoon slump in sharesyesterday. Here's Peel Hunt strategist Ian Williams: "The trigger was not immediately obvious with neither further strength in the euro, or thelatest wave of Russian diplomatic expulsions, especially convincing reasons for such a move. Amore worrying interpretation is that investors may be taking advantage of even the most modestof rallies to lighten their equity exposure." If Williams is right we may see a volatile session today as well - but for the moment allsigns are pointing to a strong rebound for the European market. (Helen Reid) ***** BULLS TO KEEP THE UPPER HAND (0548 GMT) Goldman Sachs' Bear/Bull indicator is above 70%, a level normally associated with animminent bear market (see below). But the GS team led by Peter Oppenheimer reckons relativelyattractive equity valuations will protect markets from a big drawdown, at least for now. There's also a wide spread in the underlying variables behind the indicator: very low levelsof unemployment and strong growth momentum are normally accompanied with "tighter monetarypolicy, a flatter yield curve and rising core inflation," notes GS. "But these remain subduedand without these risks rising, the prospect of a recession and 'cyclical' bear market is low." Valuation meanwhile is becoming less of a risk, they add - the forward consensus PE for theMSCI AC World is back to its 1990 average and below its average excluding Tech stocks. Highvaluations are mostly confined to the U.S. market. Furthermore, free cash flow yields have increased along with P/E ratios, and the total cashreturn from equities (dividend yield + buyback yield) has risen in most markets. So the overall message from GS is: don't panic! The bulls will prevail, at least for now... (Helen Reid) ***** MORNING CALL: EUROPEAN STOCKS TO BOUNCE BACK STRONGLY(0520 GMT) Good morning and welcome to Live Markets. Risk appetite is back! European stocks are called to open strongly higher today after a weakclose yesterday. They're being pushed up by the equities rally on Wall Street and in Asiaovernight greeting news that the U.S. and China are holding behind-the-scenes trade talks. White House officials are asking China to cut tariffs on imported cars, allow foreignmajority ownership of financial services firms and buy more U.S.-made semiconductors, accordingto a person familiar with the discussions. Asian shares bounced back overnight with the Nikkei up 1.7 percent and Chinese blue-chipsgaining 1.2 percent. The gains came after a stellar session on Wall Street with the Dowdelivering its third-biggest point gain ever, jumping 2.8 percent, while the S&P 500 gained 2.7percent and the Nasdaq surged up 3.3 percent. A negative currency effect could weigh on European stocks today, though, with the euro stillnear the six-week high against the dollar it touched yesterday. It had its biggest one-daypercentage gain since June 2017 yesterday. Spreadbetters call the DAX 183 points higher at 11,971, the CAC 40 up 60 points at 5,127,and the FTSE 100 78 points higher at 6,966. (Helen Reid) ***** (Reporting by Helen Reid, Danilo Masoni, Julien Ponthus and Kit Rees)
More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.